Evidence map›Paper›PMID 32076467›Full record

ArticleDisease markers2020

Construction and Investigation of an LINC00284-Associated Regulatory Network in Serous Ovarian Carcinoma.

Shasha Wang, Lu Zhang, Lin Tao, Lijuan Pang, Ruiting Fu, Yu Fu, Weihua Liang, Yusong Ding, Wei Jia

Open access · hybridAbstract read
In one paragraph

Article in Disease markers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shasha WangDepartment of Pathology, The First Affiliated Hospital, Shihezi University School of Medicine/Department of Pathology, Shihezi University School of Medicine/Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi, China.
Lu ZhangDepartment of Pathology, The First Affiliated Hospital, Shihezi University School of Medicine/Department of Pathology, Shihezi University School of Medicine/Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi, China.
Lin TaoDepartment of Pathology, The First Affiliated Hospital, Shihezi University School of Medicine/Department of Pathology, Shihezi University School of Medicine/Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi, China.
Lijuan PangDepartment of Pathology, The First Affiliated Hospital, Shihezi University School of Medicine/Department of Pathology, Shihezi University School of Medicine/Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi, China.ORCID https://orcid.org/0000-0003-3091-0323
Ruiting FuDepartment of Obstetrics and Gynecology, The First Affiliated Hospital School of Medicine, Shihezi University, Xinjiang 832002, China.
Yu FuDepartment of Obstetrics and Gynecology, The First Affiliated Hospital School of Medicine, Shihezi University, Xinjiang 832002, China.
Weihua LiangDepartment of Pathology, The First Affiliated Hospital, Shihezi University School of Medicine/Department of Pathology, Shihezi University School of Medicine/Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi, China.
Yusong DingDepartment of Preventive Medicine, School of Medicine, Shihezi University, Xinjiang 832002, China.
Wei JiaDepartment of Pathology, The First Affiliated Hospital, Shihezi University School of Medicine/Department of Pathology, Shihezi University School of Medicine/Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi, China.ORCID https://orcid.org/0000-0003-1248-4519
Shihezi University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The low survival rate associated with serous ovarian carcinoma (SOC) is largely due to the lack of relevant molecular markers for early detection and therapy. Increasing experimental evidence has demonstrated that long noncoding RNAs (lncRNAs) are involved in cancer initiation and development, and a competitive endogenous RNA (ceRNA) hypothesis has been formulated. Therefore, the characterization of new lncRNA and lncRNA-related networks is crucial for early diagnosis and targeted therapy of SOC. Data on lncRNAs, mRNAs, and miRNAs with differential expression in SOC, compared to normal ovarian tissue, were obtained from the Gene Expression Omnibus (GEO) database. Data on lncRNA expression and clinical data in SOC were obtained from The Cancer Genome Atlas (TCGA). lncRNA-miRNA interactions were predicted by the miRBase database. Different online tools, i.e., TargetScan, RNA22, miRmap, microT, miRanda, StarBase, and PicTar, were cooperatively utilized to predict the mRNAs targeted by miRNAs. The plugin of BiNGO in Cytoscape and KOBAS 3.0 were used to conduct the functional and pathway enrichment analyses. The lncRNA, miRNAs, and mRNAs identified to be expressed at statistically significant and different levels between SOC and healthy fallopian tube tissues were further validated using qRT-PCR. A total of 4 lncRNAs (LINC00284, HAGLR, HCAT158, and BLACAT1) and 111 mRNAs were found to be upregulated in SOC tissues compared to normal tissues, based on the GEO database. LINC00284 was found to be highly expressed in SOC, in association with the upregulation of the transcription factor SOX9. The high LINC00284 expression was associated with poor prognosis and proved to be an independent risk factor in patients with SOC, based on TCGA database. The qRT-PCR validation results closely recapitulated the expression profiles and prognostic scores of the aforementioned bioinformatic analyses. The LINC00284-related ceRNA network was found to be associated with SOC carcinogenesis by biofunctional analysis. In conclusion, the LINC00284-related ceRNA network may provide valuable information on the mechanisms of SOC initiation and progression. Importantly, LINC00284 proved to be a new potential prognostic biomarker for SOC.

Indexed as

Case-Control StudiesCystadenocarcinoma, SerousFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansKaplan-Meier EstimateNeoplasm StagingOvarian NeoplasmsPrognosisRNA, Long NoncodingUp-RegulationRNA, Long Noncoding

Identifiers

PMID32076467
PMCPMC6996679
OpenAlexW3000964475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.